A randomized clinical trial evaluating erenumab, a monoclonal antibody for chronic cluster headache (CCH), showed no significant difference in attack frequency, severity, or duration compared to placebo. Conducted with 81 patients aged 18 to 65, the study aimed to investigate if CGRP pathway inhibitors could reduce CCH attacks, given limited treatment options. Despite the administration of erenumab, primary outcomes were not met, highlighting that current CGRP-targeted therapies may be less effective for CCH than other headache types. Further research is recommended.